Skip to content

Study · Randomized controlled trial · 2009

15 results

Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes.

Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG

Endocrine journal4 Feb 2009Cited by 41 (Europe PMC)

PMID19194050 (opens in a new tab)DOI10.1507/endocrj.k08e-296 (opens in a new tab)PepBankPUB-19194050
Source linkPubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with diabetes, exenatide 2.5 microg twice daily reduced HbA1c more than placebo.

    In plain wordsIn Japanese patients with diabetes, exenatide 2.5 microg twice daily reduced HbA1c more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change at 2.5 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 microg twice daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.9%
    2.5 microg
    HbA1c change
    0.02%
    placebo

    Source sentences

    Summary
    Baseline-to-endpoint HbA1c changes (%) were +0.02 +/- 0.1 (placebo), -0.9 +/- 0.1 (2.5 microg), -1.2 +/- 0.1 (5 microg), and -1.4 +/- 0.1 (10 microg) (all p < 0.001 vs. placebo).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with diabetes, exenatide 5 microg twice daily reduced HbA1c more than placebo.

    In plain wordsIn Japanese patients with diabetes, exenatide 5 microg twice daily reduced HbA1c more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change at 5 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.2%
    5 microg
    HbA1c change
    0.02%
    placebo

    Source sentences

    Summary
    Baseline-to-endpoint HbA1c changes (%) were +0.02 +/- 0.1 (placebo), -0.9 +/- 0.1 (2.5 microg), -1.2 +/- 0.1 (5 microg), and -1.4 +/- 0.1 (10 microg) (all p < 0.001 vs. placebo).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with diabetes, the exenatide 10 microg twice-daily arm reduced HbA1c more than placebo.

    In plain wordsIn Japanese patients with diabetes, the exenatide 10 microg twice-daily arm reduced HbA1c more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change at 10 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice daily for 4 weeks, then 10 microg twice daily for 8 weeks · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.4%
    10 microg
    HbA1c change
    0.02%
    placebo

    Source sentences

    Summary
    Baseline-to-endpoint HbA1c changes (%) were +0.02 +/- 0.1 (placebo), -0.9 +/- 0.1 (2.5 microg), -1.2 +/- 0.1 (5 microg), and -1.4 +/- 0.1 (10 microg) (all p < 0.001 vs. placebo).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In the reported baseline HbA1c subgroup, 50.0% reached HbA1c below 7% with exenatide 2.5 microg versus 5.1% with placebo.

    In plain wordsIn the reported baseline HbA1c subgroup, 50.0% reached HbA1c below 7% with exenatide 2.5 microg versus 5.1% with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c below 7% at 2.5 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 microg twice daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    HbA1c below 7%
    50%
    2.5 microg
    HbA1c below 7%
    5.1%
    placebo

    Source sentences

    Summary
    Of patients with baseline HbA1c -7%, 5.1% (placebo), 50.0% (2.5 microg), 71.4% (5 microg), and 79.4% (10 microg) achieved HbA1c <7% at endpoint (p < 0.001, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In the reported baseline HbA1c subgroup, 71.4% reached HbA1c below 7% with exenatide 5 microg versus 5.1% with placebo.

    In plain wordsIn the reported baseline HbA1c subgroup, 71.4% reached HbA1c below 7% with exenatide 5 microg versus 5.1% with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c below 7% at 5 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    HbA1c below 7%
    71.4%
    5 microg
    HbA1c below 7%
    5.1%
    placebo

    Source sentences

    Summary
    Of patients with baseline HbA1c -7%, 5.1% (placebo), 50.0% (2.5 microg), 71.4% (5 microg), and 79.4% (10 microg) achieved HbA1c <7% at endpoint (p < 0.001, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In the reported baseline HbA1c subgroup, 79.4% reached HbA1c below 7% with exenatide 10 microg versus 5.1% with placebo.

    In plain wordsIn the reported baseline HbA1c subgroup, 79.4% reached HbA1c below 7% with exenatide 10 microg versus 5.1% with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c below 7% at 10 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice daily for 4 weeks, then 10 microg twice daily for 8 weeks · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    HbA1c below 7%
    79.4%
    10 microg
    HbA1c below 7%
    5.1%
    placebo

    Source sentences

    Summary
    Of patients with baseline HbA1c -7%, 5.1% (placebo), 50.0% (2.5 microg), 71.4% (5 microg), and 79.4% (10 microg) achieved HbA1c <7% at endpoint (p < 0.001, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with diabetes, exenatide 2.5 microg twice daily reduced fasting plasma glucose more than placebo.

    In plain wordsIn Japanese patients with diabetes, exenatide 2.5 microg twice daily reduced fasting blood glucose more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting plasma glucose change at 2.5 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 microg twice daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose change
    −18.6 mg/dL
    2.5 microg
    Fasting plasma glucose change
    6 mg/dL
    placebo

    Source sentences

    Summary
    Baseline-to-endpoint fasting plasma glucose changes (mg/dL) were +6.0 +/- 4.8 (placebo), -18.6 +/- 5.7 (2.5 microg), -25.0 +/- 7.0 (5 microg), and -28.9 +/- 5.9 (10 microg) (all p < or = 0.001 vs. placebo).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with diabetes, exenatide 5 microg twice daily reduced fasting plasma glucose more than placebo.

    In plain wordsIn Japanese patients with diabetes, exenatide 5 microg twice daily reduced fasting blood glucose more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting plasma glucose change at 5 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice daily · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose change
    −25 mg/dL
    5 microg
    Fasting plasma glucose change
    6 mg/dL
    placebo

    Source sentences

    Summary
    Baseline-to-endpoint fasting plasma glucose changes (mg/dL) were +6.0 +/- 4.8 (placebo), -18.6 +/- 5.7 (2.5 microg), -25.0 +/- 7.0 (5 microg), and -28.9 +/- 5.9 (10 microg) (all p < or = 0.001 vs. placebo).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with diabetes, the exenatide 10 microg twice-daily arm reduced fasting plasma glucose more than placebo.

    In plain wordsIn Japanese patients with diabetes, the exenatide 10 microg twice-daily arm reduced fasting blood glucose more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting plasma glucose change at 10 microg BID
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 microg twice daily for 4 weeks, then 10 microg twice daily for 8 weeks · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose change
    −28.9 mg/dL
    10 microg
    Fasting plasma glucose change
    6 mg/dL
    placebo

    Source sentences

    Summary
    Baseline-to-endpoint fasting plasma glucose changes (mg/dL) were +6.0 +/- 4.8 (placebo), -18.6 +/- 5.7 (2.5 microg), -25.0 +/- 7.0 (5 microg), and -28.9 +/- 5.9 (10 microg) (all p < or = 0.001 vs. placebo).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  10. 10HumanRandomized controlled trialSafety outcome

    In the Japanese diabetes trial of exenatide, treatment-emergent adverse events were mostly mild.

    In plain wordsIn the Japanese diabetes trial of exenatide, adverse events were mostly mild.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableTreatment-emergent adverse event severity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment-emergent adverse events were mostly mild; dose-dependent increases in incidence were observed for hypoglycemia, nausea, anorexia, decreased appetite, and diarrhea (all p < or = 0.044, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  11. 11HumanRandomized controlled trialSafety outcome

    In Japanese patients with diabetes, hypoglycemia incidence increased with exenatide dose.

    In plain wordsIn Japanese patients with diabetes, low blood glucose became more frequent as exenatide dose increased.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDose-dependent hypoglycemia incidence
    Study

    n: not reported in source

    Comparator
    Placebo and lower exenatide doses (trend test across dose groups)
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment-emergent adverse events were mostly mild; dose-dependent increases in incidence were observed for hypoglycemia, nausea, anorexia, decreased appetite, and diarrhea (all p < or = 0.044, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  12. 12HumanRandomized controlled trialSafety outcome

    In Japanese patients with diabetes, nausea incidence increased with exenatide dose.

    In plain wordsIn Japanese patients with diabetes, nausea became more frequent as exenatide dose increased.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDose-dependent nausea incidence
    Study

    n: not reported in source

    Comparator
    Placebo and lower exenatide doses (trend test across dose groups)
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment-emergent adverse events were mostly mild; dose-dependent increases in incidence were observed for hypoglycemia, nausea, anorexia, decreased appetite, and diarrhea (all p < or = 0.044, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  13. 13HumanRandomized controlled trialSafety outcome

    In Japanese patients with diabetes, anorexia incidence increased with exenatide dose.

    In plain wordsIn Japanese patients with diabetes, anorexia became more frequent as exenatide dose increased.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDose-dependent anorexia incidence
    Study

    n: not reported in source

    Comparator
    Lower dose groups
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2.5, 5 or 10 microg BID · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment-emergent adverse events were mostly mild; dose-dependent increases in incidence were observed for hypoglycemia, nausea, anorexia, decreased appetite, and diarrhea (all p < or = 0.044, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  14. 14HumanRandomized controlled trialSafety outcome

    In Japanese patients with diabetes, decreased appetite incidence increased with exenatide dose.

    In plain wordsIn Japanese patients with diabetes, decreased appetite became more frequent as exenatide dose increased.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDose-dependent decreased appetite incidence
    Study

    n: not reported in source

    Comparator
    Lower dose groups
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2.5, 5 or 10 microg BID · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment-emergent adverse events were mostly mild; dose-dependent increases in incidence were observed for hypoglycemia, nausea, anorexia, decreased appetite, and diarrhea (all p < or = 0.044, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.
  15. 15HumanRandomized controlled trialSafety outcome

    In Japanese patients with diabetes, diarrhea incidence increased with exenatide dose.

    In plain wordsIn Japanese patients with diabetes, diarrhea became more frequent as exenatide dose increased.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDose-dependent diarrhea incidence
    Study

    n: not reported in source

    Comparator
    Lower dose groups
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.5, 5 or 10 microg BID · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment-emergent adverse events were mostly mild; dose-dependent increases in incidence were observed for hypoglycemia, nausea, anorexia, decreased appetite, and diarrhea (all p < or = 0.044, trend test).
    3 context sentences
    Summary · context
    This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione.
    Summary · context
    Patients were randomly assigned to placebo (N = 40), 2.5 microg (N = 38), 5 microg (N = 37), or 10 microg (N = 38) exenatide administered subcutaneously twice daily (BID).
    Summary · context
    Patients randomly assigned to 10 microg exenatide received 5 microg BID for the first 4 weeks, with the dose escalated to 10 microg BID for the final 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00382239

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

AstraZenecan = 153Sept 2006 to May 2007

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 23 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.